Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Author:

Eggermont Alexander M.M.12,Kicinski Michal3,Blank Christian U.4,Mandala Mario5,Long Georgina V.6,Atkinson Victoria7,Dalle Stéphane8,Haydon Andrew9,Meshcheryakov Andrey10,Khattak Adnan11,Carlino Matteo S.12,Sandhu Shahneen13,Larkin James14,Puig Susana15,Ascierto Paolo A.16,Rutkowski Piotr17,Schadendorf Dirk1819,Boers-Sonderen Marye20,Di Giacomo Anna Maria21,van den Eertwegh Alfonsus J.M.22,Grob Jean-Jacques23,Gutzmer Ralf24,Jamal Rahima25,van Akkooi Alexander C.J.26,Lorigan Paul27,Grebennik Dmitri28,Krepler Clemens28,Marreaud Sandrine3,Suciu Stefan3,Robert Caroline29

Affiliation:

1. Comprehensive Cancer Center Munich, München, Germany

2. Princess Máxima Center and University Medical Center Utrecht, Netherlands

3. European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

4. Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, the Netherlands

5. University of Perugia, Santa Maria della Misericordia Hospital, Italy

6. Melanoma Institute Australia, University of Sydney, Mater and Royal North Shore Hospitals, Sydney, VIC, Australia

7. Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia

8. Lyon Civic Hospital Cancer Institute, Cancer Research Centre of Lyon, Lyon University, France

9. Alfred Hospital, Melbourne, VIC, Australia

10. Federal State Budgetary Institution “Russian Oncology Scientific Centre named after N.N. Blokhin RAMS,” Moscow, Russian Federation

11. Fiona Stanley Hospital/University of Western Australia, Perth, WA, Australia

12. Westmead and Blacktown Hospitals, Melanoma Institute Australia, and University of Sydney, Sydney, VIC, Australia

13. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

14. The Royal Marsden Hospital, London

15. Hospital Clínic de Barcelona, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain

16. Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy

17. Maria Sklodowska-Curie Institute–Oncology Center, Warsaw, Poland

18. University Hospital Essen, Essen, Germany

19. German Cancer Consortium, Heidelberg, Germany

20. Radboud University Medical Center, Nijmegen, the Netherlands

21. Center for Immuno-Oncology and Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Italy

22. VU University Medical Center, Amsterdam

23. Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, France

24. Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Germany

25. Centre Hospitalier de l’Université de Montréal, Centre de Recherche du CHUM, Quebec, QC, Canada

26. Melanoma Institute Australia, University of Sydney, Sydney, VIC, Australia

27. Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, United Kingdom

28. Merck & Co., Inc., Rahway, USA

29. Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, France

Publisher

Massachusetts Medical Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3